Quantcast

Latest Tapentadol Stories

2011-07-18 03:45:00

SYDNEY and BEDMINSTER, N.J., July 18, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA).

2011-06-29 07:40:00

More comprehensive statistical analysis shows MoxDuo IR, at equi-analgesic doses to either Morphine or Oxycodone, produced significantly less severe respiratory depression SYDNEY and BEDMINSTER, N.J., June 29, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the release of additional data on its Phase 3 safety study for MoxDuo IR.

2011-06-07 08:00:00

SAN FRANCISCO, June 7, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate.

2011-05-31 20:40:00

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc.

2011-05-17 15:00:00

WASHINGTON, May 17, 2011 /PRNewswire/ -- New data presented today show that RAPAFLO(R) (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

2011-04-22 07:23:00

TALLAHASSEE, Fla., April 22, 2011 /PRNewswire/ -- The Florida Society of Pain Management Providers (www.Flspmp.org) urges Government, Law Enforcement and the media to stop using false prescription drug data and statistics.

2011-04-21 08:57:00

CAMBRIDGE, England, April 21, 2011 /PRNewswire/ -- - First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun. The trial is a randomised, placebo...

2011-04-14 07:31:00

SYDNEY, Australia and BEDMINSTER, N.J., April 14, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029.

2011-04-04 07:01:00

NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc.

2011-03-30 07:00:00

SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer. In this role, Dr.


Word of the Day
postliminy
  • In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
  • In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.
The word 'postliminy' comes from a Latin word meaning 'threshold'.